The safety of achieved iron stores and their effect on IV iron and ESA use: post-hoc results from a randomized trial of ferric citrate as a phosphate binder in dialysis

2017 ◽  
Vol 87 (03) ◽  
pp. 124-133 ◽  
Author(s):  
Kausik Umanath ◽  
Barbara Greco ◽  
Diana Jalal ◽  
Molly McFadden ◽  
Mohammed Sika ◽  
...  
Keyword(s):  
Randomized Trial ◽  
Phosphate Binder ◽  
Ferric Citrate ◽  
Iron Stores ◽  
Iv Iron ◽  
Post Hoc

Oral Low-Dose Ferric Citrate Is a Useful Iron Source for Hyperphosphatemic Hemodialysis Patients: A Case Series

2016 ◽  
Vol 43 (1-3) ◽  
pp. 97-100 ◽  
Author(s):  
Masayuki Tanemoto ◽  
Yu Ishimoto ◽  
Hisako Saito
Keyword(s):  
Phosphate Binder ◽  
Low Dose ◽  
Transferrin Saturation ◽  
Case Series ◽  
Ferric Citrate ◽  
Phosphate Binders ◽  
Iron Stores ◽  
Median Serum ◽  
Iron Deficient ◽  
Iron Parameters

Background: Randomized trials have demonstrated that a phosphate binder ferric citrate (FeC) increases iron parameters in comparison with other phosphate binders, but the doses for FeC to improve iron stores safely have not been clarified. Methods: We examined changes of iron parameters and blood hemoglobin (Hb) in 7 iron-deficient hemodialysis (HD) patients taking FeC 750 mg/day as a phosphate binder. Results: The median serum transferrin saturation and ferritin increased from 13% (interquartile range (IQR) 7-18) to 28% (IQR 22-31; p = 0.010) and from 17 ng/ml (IQR 11-60) to 106 ng/ml (IQR 58-176; p = 0.015) by 2 and 3 months respectively. With the persistence of these levels thereafter, the FeC administration reduced the usage of erythropoiesis-stimulating agents while maintaining adequate blood Hb levels. Conclusion: Oral FeC 750 mg/day improves iron stores without inducing iron overload in hyperphosphatemic HD patients.

Ferric citrate in end-stage kidney disease as a phosphate binder and source of iron: a review of clinical trials

2015 ◽  
Vol 5 (6) ◽  
pp. 551-559
Author(s):  
Diana I Jalal ◽  
Mohammed Sika ◽  
Jamie P Dwyer ◽  
Ingrid J Chang ◽  
Barbara A Greco ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Kidney Disease ◽  
Phosphate Binder ◽  
Ferric Citrate ◽  
End Stage Kidney Disease ◽  
End Stage

Dose-Response and Efficacy of Ferric Citrate to Treat Hyperphosphatemia in Hemodialysis Patients: A Short-term Randomized Trial

2013 ◽  
Vol 61 (5) ◽  
pp. 759-766 ◽  
Author(s):  
Jamie P. Dwyer ◽  
Mohammed Sika ◽  
Gerald Schulman ◽  
Ingrid J. Chang ◽  
Michael Anger ◽  
...  
Keyword(s):  
Randomized Trial ◽  
Dose Response ◽  
Hemodialysis Patients ◽  
Ferric Citrate ◽  
Short Term

Cytochrome c in patients undergoing coronary artery bypass grafting: A post hoc analysis of a randomized trial

2017 ◽  
Vol 42 ◽  
pp. 248-254
Author(s):  
Lars W. Andersen ◽  
Xiaowen Liu ◽  
Sophia Montissol ◽  
Mathias J. Holmberg ◽  
Bjørn K. Fabian-Jessing ◽  
...  
Keyword(s):  
Coronary Artery ◽  
Coronary Artery Bypass Grafting ◽  
Cytochrome C ◽  
Randomized Trial ◽  
Coronary Artery Bypass ◽  
Artery Bypass ◽  
Bypass Grafting ◽  
Artery Bypass Grafting ◽  
Post Hoc Analysis ◽  
Post Hoc

scholarly journals FERRIC CITRATE: AN IRON-BASED ORAL PHOSPHATE BINDER

2012 ◽  
Vol 31 (2) ◽  
pp. A38-A39 ◽  
Author(s):  
T. Christopher Bond ◽  
Rich Mutell ◽  
Stephen Wang ◽  
Enrique Poradosu ◽  
Tracy Robert Niecestro
Keyword(s):  
Phosphate Binder ◽  
Ferric Citrate ◽  
Iron Based

scholarly journals Iron Deficiency in Chronic Kidney Disease: Updates on Pathophysiology, Diagnosis, and Treatment

2020 ◽  
Vol 31 (3) ◽  
pp. 456-468 ◽  
Author(s):  
Elizabeth Katherine Batchelor ◽  
Pinelopi Kapitsinou ◽  
Pablo E. Pergola ◽  
Csaba P. Kovesdy ◽  
Diana I. Jalal
Keyword(s):  
Iron Deficiency ◽  
Iron Supplementation ◽  
Deficiency Anemia ◽  
Iron Stores ◽  
Iv Iron ◽  
Potential Risks ◽  
Liberal Approach ◽  
Absolute Iron Deficiency ◽  
Relative Deficiency ◽  
Reduced Kidney Function

Anemia is a complication that affects a majority of individuals with advanced CKD. Although relative deficiency of erythropoietin production is the major driver of anemia in CKD, iron deficiency stands out among the mechanisms contributing to the impaired erythropoiesis in the setting of reduced kidney function. Iron deficiency plays a significant role in anemia in CKD. This may be due to a true paucity of iron stores (absolute iron deficiency) or a relative (functional) deficiency which prevents the use of available iron stores. Several risk factors contribute to absolute and functional iron deficiency in CKD, including blood losses, impaired iron absorption, and chronic inflammation. The traditional biomarkers used for the diagnosis of iron-deficiency anemia (IDA) in patients with CKD have limitations, leading to persistent challenges in the detection and monitoring of IDA in these patients. Here, we review the pathophysiology and available diagnostic tests for IDA in CKD, we discuss the literature that has informed the current practice guidelines for the treatment of IDA in CKD, and we summarize the available oral and intravenous (IV) iron formulations for the treatment of IDA in CKD. Two important issues are addressed, including the potential risks of a more liberal approach to iron supplementation as well as the potential risks and benefits of IV versus oral iron supplementation in patients with CKD.

Desensitization in Iron Product Allergy

2020 ◽  
Vol 143 (5) ◽  
pp. 496-499
Author(s):  
Attilio Di Girolamo ◽  
Marcello Albanesi ◽  
Filomena Loconte ◽  
Danilo Di Bona ◽  
Maria Filomena Caiaffa ◽  
...  
Keyword(s):  
Iron Deficiency ◽  
Complement Activation ◽  
Therapeutic Target ◽  
Iron Therapy ◽  
Safe Procedure ◽  
Hypersensitivity Reactions ◽  
Iron Stores ◽  
Immunological Responses ◽  
Iv Iron ◽  
Ige Mediated

Iron deficiency is the main cause of anemia in both sexes, with women being more commonly affected. Iron therapy is currently considered an effective and safe remedy to replenish the iron storages. Iron can be administrated both orally and intravenously. In particular, intravenous (IV) iron therapy is widely used when oral iron preparations are either not tolerated or ineffective. Indeed, IV iron improves iron stores more rapidly. Two main immunological responses have been described for iron hypersensitivity reactions (HSRs): IgE-mediated allergy and complement activation-related pseudo-allergy. Here, we report 3 cases of adult patients with iron allergy, who were successfully treated with two different desensitization procedures, respectively. Analysis of these cases demonstrates that, in the presence of HSRs to iron products, desensitization is an effective and safe procedure that prevents treatment discontinuation and hence allows therapeutic target achievement.

Sign in / Sign up

Export Citation Format

Share Document